The disease relevance of human hepatocellular xenograft models: Molecular characterization and review of the literature

Cancer Letters

Volumn 286, Issue 1, 2009, Pages 121-128

  Kashofer, K ^a   Tschernatsch, M M ^a   Mischinger, H J ^a   Iberer, F ^a   Zatloukal, K ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Gene expression profiles; HCC; Hepatocellular carcinoma; Xenografts

Indexed keywords

ANTINEOPLASTIC AGENT; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; RAS PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; CANCER CELL CULTURE; CANCER RESEARCH; CELL DIVISION; CONTROLLED STUDY; DISEASE MODEL; DRUG SCREENING; DRUG TARGETING; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; TUMOR XENOGRAFT; XENOTRANSPLANTATION;

EID: 70350571760     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.11.011     Document Type: Review

References (46)

1. Villanueva A., Newell P., Chiang D.Y., Friedman S.L., and Llovet J.M. Genomics and signaling pathways in hepatocellular carcinoma. Semin. Liver Dis. 27 (2007) 55-76
2. Sheu J.C. Molecular mechanism of hepatocarcinogenesis. J. Gastroenterol. Hepatol. 12 (1997) S309-S313
3. Thorgeirsson S.S., and Grisham J.W. Molecular pathogenesis of human hepatocellular carcinoma. Nat. Genet. 31 (2002) 339-346
4. Giannelli G., and Antonaci S. Novel concepts in hepatocellular carcinoma: from molecular research to clinical practice. J. Clin. Gastroenterol. 40 (2006) 842-846
5. Kira S., Nakanishi T., Suemori S., Kitamoto M., Watanabe Y., and Kajiyama G. Expression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocellular carcinoma. Liver 17 (1997) 177-182
6. Harada K., Shiota G., and Kawasaki H. Transforming growth factor-alpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma. Liver 19 (1999) 318-325
7. Yamaguchi K., Carr B.I., and Nalesnik M.A. Concomitant and isolated expression of TGF-alpha and EGF-R in human hepatoma cells supports the hypothesis of autocrine, paracrine, and endocrine growth of human hepatoma. J. Surg. Oncol. 58 (1995) 240-245
8. Thomas M.B., Chadha R., Glover K., Wang X., Morris J., Brown T., et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 110 (2007) 1059-1067
9. Zhu A.X., Stuart K., Blaszkowsky L.S., Muzikansky A., Reitberg D.P., Clark J.W., et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 110 (2007) 581-589
10. Yamaguchi R., Yano H., Iemura A., Ogasawara S., Haramaki M., and Kojiro M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 28 (1998) 68-77
11. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350 (2004) 2335-2342
12. Zhu A.X., Blaszkowsky L.S., Ryan D.P., Clark J.W., Muzikansky A., Horgan K., et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 24 (2006) 1898-1903
13. Hotte S.J., and Hirte H.W. BAY 43-9006: early clinical data in patients with advanced solid malignancies. Curr. Pharm. Des. 8 (2002) 2249-2253
14. Abou-Alfa G.K., Schwartz L., Ricci S., Amadori D., Santoro A., Figer A., et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 24 (2006) 4293-4300
15. Hanna N., Davis T.W., and Fidler I.J. Environmental and genetic factors determine the level of NK activity of nude mice and affect their suitability as models for experimental metastasis. Int. J. Cancer 30 (1982) 371-376
16. Venditti J.M., Wesley R.A., and Plowman J. Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976-1982, and future directions. Adv. Pharmacol. Chemother. 20 (1984) 1-20
17. Hollingshead M.G., Alley M.C., Camalier R.F., Abbott B.J., Mayo J.G., Malspeis L., et al. In vivo cultivation of tumor cells in hollow fibers. Life Sci. 57 (1995) 131-141
18. Johnson J.I., Decker S., Zaharevitz D., Rubinstein L.V., Venditti J.M., Schepartz S., et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br. J. Cancer 84 (2001) 1424-1431
19. Lee J., Chu I., Mikaelyan A., Calvisi D.F., Heo J., Reddy J.K., et al. Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat. Genet. 36 (2004) 1306-1311
20. Lee H.S., Huang A.M., Huang G.T., Yang P.M., Chen P.J., Sheu J.C., et al. Hepatocyte growth factor stimulates the growth and activates mitogen-activated protein kinase in human hepatoma cells. J. Biomed. Sci. 5 (1998) 180-184
21. Aden D.P., Fogel A., Plotkin S., Damjanov I., and Knowles B.B. Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature 282 (1979) 615-616
22. Fogh J., Fogh J.M., and Orfeo T. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst. 59 (1977) 221-226
23. Wang S., Pan S., Peng C., Huang D., Tsai A., Chang Y., et al. CHM-1 inhibits hepatocyte growth factor-induced invasion of SK-Hep-1 human hepatocellular carcinoma cells by suppressing matrix metalloproteinase-9 expression. Cancer Lett. 257 (2007) 87-96
24. Oh G.S., Pae H.O., Oh H., Hong S.G., Kim I.K., Chai K.Y., et al. In vitro anti-proliferative effect of 1,2,3,4,6-penta-O-galloyl-beta-d-glucose on human hepatocellular carcinoma cell line, SK-HEP-1 cells. Cancer Lett. 174 (2001) 17-24
25. Heffelfinger S.C., Hawkins H.H., Barrish J., Taylor L., and Darlington G.J. SK HEP-1: a human cell line of endothelial origin. In Vitro Cell Dev. Biol. 28A (1992) 136-142
26. Suggitt M., and Bibby M.C. 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin. Cancer Res. 11 (2005) 971-981
27. Schein P.S., and Scheffler B. Barriers to efficient development of cancer therapeutics. Clin. Cancer Res. 12 (2006) 3243-3248
28. Flanagan S.P. 'Nude', a new hairless gene with pleiotropic effects in the mouse. Genet. Res. 8 (1966) 295-309
29. Wortis H.H., Nehlsen S., and Owen J.J. Abnormal development of the thymus in "nude" mice. J. Exp. Med. 134 (1971) 681-692
30. Rygaard J., and Povlsen C.O. Heterotransplantation of a human malignant tumour to "Nude" mice. Acta Pathol. Microbiol. Scand. 77 (1969) 758-760
31. Giovanella B.C., Yim S.O., Stehlin J.S., and Williams L.J.J. Development of invasive tumors in the "nude" mouse after injection of cultured human melanoma cells. J. Natl. Cancer Inst. 48 (1972) 1531-1533
32. Nehls M., Pfeifer D., Schorpp M., Hedrich H., and Boehm T. New member of the winged-helix protein family disrupted in mouse and rat nude mutations. Nature 372 (1994) 103-107
33. Kaestner K.H., Knochel W., and Martinez D.E. Unified nomenclature for the winged helix/forkhead transcription factors. Genes Dev. 14 (2000) 142-146
34. Bosma G.C., Custer R.P., and Bosma M.J. A severe combined immunodeficiency mutation in the mouse. Nature 301 (1983) 527-530
35. Blunt T., Finnie N.J., Taccioli G.E., Smith G.C., Demengeot J., Gottlieb T.M., et al. Defective DNA-dependent protein kinase activity is linked to V(D)J recombination and DNA repair defects associated with the murine scid mutation. Cell 80 (1995) 813-823
36. Habu S., Fukui H., Shimamura K., Kasai M., Nagai Y., Okumura K., et al. In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. J. Immunol. 127 (1981) 34-38
37. Shultz L.D., Schweitzer P.A., Christianson S.W., Gott B., Schweitzer I.B., Tennent B., et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J. Immunol. 154 (1995) 180-191
38. Bioulac-Sage P., Rebouissou S., Thomas C., Blanc J., Saric J., Sa Cunha A., et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology 46 (2007) 740-748
39. Austinat M., Dunsch R., Wittekind C., Tannapfel A., Gebhardt R., and Gaunitz F. Correlation between beta-catenin mutations and expression of Wnt-signaling target genes in hepatocellular carcinoma. Mol. Cancer 7 (2008) 21
40. Mauad T.H., van Nieuwkerk C.M., Dingemans K.P., Smit J.J., Schinkel A.H., Notenboom R.G., et al. Mice with homozygous disruption of the mdr2 P-glycoprotein gene, a novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am. J. Pathol. 145 (1994) 1237-1245
41. Thomas C., and Schmaehl D. On the morphology of diethylnitrosamine-induced liver tumors in mice and guinea pigs. Z. Krebsforsch. 65 (1963) 531-536
42. Zhao L., Mou D., Leng X., Peng J., Wang W., Huang L., et al. Expression of cancer-testis antigens in hepatocellular carcinoma. World J. Gastroenterol. 10 (2004) 2034-2038
43. Kanehisa M., Araki M., Goto S., Hattori M., Hirakawa M., Itoh M., et al. KEGG for linking genomes to life and the environment. Nucleic Acids Res. 36 (2008) D480-D484
44. Kanehisa M., Goto S., Hattori M., Aoki-Kinoshita K.F., Itoh M., Kawashima S., et al. From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res. 34 (2006) D354-D357
45. Kanehisa M., and Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28 (2000) 27-30
46. Taylor D.S., Cheng X., Pawlowski J.E., Wallace A.R., Ferrer P., and Molloy C.J. Epiregulin is a potent vascular smooth muscle cell-derived mitogen induced by angiotensin II, endothelin-1, and thrombin. Proc. Natl. Acad. Sci. USA 96 (1999) 1633-1638